Amalgamated Financial’s Acumen Pharmaceuticals ABOS Stock Holding History

Amalgamated Financial’s Portfolio ABOS Stock Details ABOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$15K	Buy	+3,896	New	+$21.2K	﹤0.01%	2810

Other funds holding ABOS

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Guardian Point Capital Charlottesville, Virginia $243M AUM 22.43% 1-Year Est. Return

Amalgamated Financial's ABOS Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Acumen Pharmaceuticals (ABOS) in Q1 2022: 3,896 shares worth $15K. The stake represents ﹤0.01% of the portfolio and ranks #2810 among its holdings.

57 funds tracked by Wall St. Rank hold ABOS as of Q1 2022.

Amalgamated Financial held 3,896 shares of Acumen Pharmaceuticals worth $15K as of Q1 2022.
Acumen Pharmaceuticals was a new Amalgamated Financial position in Q1 2022.
Acumen Pharmaceuticals made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2810 holding.
57 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.